Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
Establishment of new precision molecular oncology research center to drive development of novel targeted cancer therapies for patients with unmet medical need / Strategic investment of $140M USD to expand presence in leading center of biotech innovation at Kendall Square in Cambridge / Fostering close collaboration with scientists, enhancing global network of academic, hospital and industry partners located in Boston scientific hub
Information
Title
Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology